Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Common Equity (2016 - 2025)

Orthofix Medical's Common Equity history spans 17 years, with the latest figure at $450.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 10.55% year-over-year to $450.0 million, compared with a TTM value of $450.0 million through Dec 2025, down 10.55%, and an annual FY2025 reading of $450.0 million, down 10.55% over the prior year.
  • Common Equity for Q4 2025 was $450.0 million at Orthofix Medical, up from $442.5 million in the prior quarter.
  • The five-year high for Common Equity was $664.2 million in Q1 2023, with the low at $333.5 million in Q3 2022.
  • Average Common Equity over 5 years is $462.0 million, with a median of $454.2 million recorded in 2025.
  • Year-over-year, Common Equity skyrocketed 97.92% in 2023 and then decreased 19.64% in 2025.
  • Tracing OFIX's Common Equity over 5 years: stood at $336.9 million in 2021, then fell by 0.02% to $336.9 million in 2022, then skyrocketed by 77.74% to $598.7 million in 2023, then decreased by 15.97% to $503.1 million in 2024, then decreased by 10.55% to $450.0 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's Common Equity are $450.0 million (Q4 2025), $442.5 million (Q3 2025), and $458.3 million (Q2 2025).